MONMOUTH JUNCTION, NJ.– Pharmaceutical companies and clinical laboratories are using dried blood spot (DBS) technology for newborn screening of metabolic disorders, epidemiological surveys (e.g. HIV monitoring), therapeutic drug monitoring (TDM) and toxicology analysis. Hemoglobin is a common contaminant in whole blood. Hemoglobin causes increased blood procoagulant activity which is thought to be a marker of macrophage activation. Spectrophotometric and other procedures are implemented to test for hemoglobin (Hb) contamination in tissues. HemoVoid™ is a silica based NuGel™ polyelectrolyte matrix and it removes hemoglobin from dried whole blood card. The HemoVoid™ protocol uses mild buffers and the protocol conditions are so gentle that native enzyme and other functional activity is retained in elution fractions. After implementing the HemoVoid™ Blood Card protocol it produces enriched proteins free of hemoglobin which are used for biomarkers and protein analysis. The hemoglobin enriched filtrate could have hemoglobin variants, hemoglobin binding proteins or other analytes optimal for biomarker studies. HemoVoid™ Blood Card protocol is compatible with validated LC-MS/MS assays.
Advantages of Dried Blood Spot are:
1.Convenience: DBS does not require venipuncture, use of anticoagulant or plasma separation. Compatible with analytical approaches used by pharmaceutical companies and clinical laboratories allowing for automated handling of DBS samples without pretreatment.
2.Small sample volume: Venous sampling requires more volume. DBS volume is less than 20ul on filter paper. Dried blood spot (DBS) analysis has substantially reduced the volume of blood needed. Ethical benefits for preclinical studies are reduced volumes, removal of satellite requirement on short term toxicology studies and reduction of rodent warming.
3.Cost effective: DBS samples could be stored at room temperature without dry ice thus reducing cost of shipping and storage of filter papers.
4.Analyte stability : DBS samples stored for months to years are similar to plasma samples stored at -20 degrees C and provide greater metabolite stability.
5.Increased safety: Drying causes pathogens to deactivate on the filter paper and transfer of blood onto filter paper has low infection risk.
Characteristics of Hemovoid™
Greater than 98% hemoglobin voids in flow-through , with less than 30 minute bind/wash/elute protocol.
Hemoglobin removal from whole blood lysates extracted from dried blood cards.
Hemoglobin removal from frozen and fresh blood.
Hemoglobin removal from erythrocytes (red blood cells).
Blood proteins and enzymes are enriched for potential biomarker and proteomic studies.
Disposable, cost-effective and high throughput hemoglobin depletion method.
Removes hemoglobin from whole blood of diverse species including human, mice, sheep, bovine, goat, rat, etc.
HemoVoid™ protocol is designed to substantially reduce the presence of hemoglobin and it’s associated interference with many serum protein analytes.
For more information click here:
http://www.biotechsupportgroup.com/node/238
CONTACT:
Dr.Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
732-274-2866
sales@biotechsupportgroup.com
Hemovoid™ References
1.Katja Walpurgis, Maxie Kohler, Andreas Thomas et al.Validated hemoglobin-depletion approach for red blood cell lysate proteome analysis by means of 2D-PAGE and Orbitrap MS.Electrophoresis.2012;
2. Mizukawa, B., George, A., Pushkaran, S. et al. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis.Pediatric Blood Cancer.2011;56: 840-842.
3. Sudha Neelam, David G Kakhniashvili, Stephan Wilkens et al. Functional 20S proteasomes in mature human red blood cells Experimental Biology and Medicine.2011;236:580-591
Suggested References
1.Lorell Discenza, Mary T Obermeier, Richard Westhouse, Timothy V Olah, Celia J D’Arienzo. A bioanalytical strategy utilizing dried blood spot sampling and LC–MS/MS in discovery toxicology studies. Bioanalysis.2012;4(9):1057-1064
2.Katja Heinig, Thomas Wirz, Franz Bucheli, Almudena Gajate-Perez. Determination of oseltamivir (Tamiflu®) and oseltamivir carboxylate in dried blood spots using offline or online extraction. Bioanalysis.2011;3(4):421-437
3.Graeme T Clark, Julian J Haynes. Utilization of DBS within drug discovery: a simple 2D-LC–MS/MS system to minimize blood- and paper-based matrix effects from FTA elute™ DBS. Bioanalysis.2011; 3(11):1253-1270
4.Enaksha R Wickremsinhe, Basira G Abdul, Naijia H Huang, John W Richard, Jennifer L Hanes, Kenneth J Ruterbories, Everett J Perkins, Ajai K Chaudhary. Dried blood spot sampling: coupling bioanalytical feasibility, blood–plasma partitioning and transferability to in vivo preclinical studies. Bioanalysis. 2011;3(14):1635-1646
5.Guowen Liu, Laura Patrone, Heidi M Snapp, Alicja Batog, Jack Valentine, Greg Cosma, Adrienne Tymiak, Qin C Ji, and Mark E Arnold. Evaluating and defining sample preparation procedures for DBS LC–MS/MS assays Bioanalysis.2010; 2(8):1405-1414
6.Li, W. and Tse, F. L. S. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr.2010; 24: 49-65
7.Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens.Journal of Nutrition.2001;131:1631S-1636S
8.Parker, S. P. & Cubitt, D. W. The use of the dried blood spot sample in epidemiological studies.Journal of Clinical Pathology.1999.52:633-639.
9.McCabe, E. R. B.Utility of PCR for DNA analysis from dried-blood spots on filter paper blotters.PCR Methods and Applications.1991.1:99-106.
